Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Feb 11, 2026
Datadog (DDOG) Stock Analysis: AI Growth Narrative Intact After Sharp Pullback

Datadog (DDOG) Stock Analysis: AI Growth Narrative Intact After Sharp Pullback

Key Takeaways

  • Datadog (DDOG) shares have retreated roughly 10–15% in recent weeks, lagging broader markets amid software sector weakness and pre-earnings caution.

  • Wall Street sentiment remains constructive, with a Buy-weighted analyst consensus and average price targets near $194 implying meaningful upside.

  • Q3 2025 results delivered 28% revenue growth to $886 million, alongside a notable EPS beat and strong expansion in AI-native and security-related ARR.

  • An expanded AWS partnership and new AI-driven offerings, including Bits AI SRE, reinforce Datadog’s leadership in observability and cloud security.

  • Q4 earnings on February 10, 2026, are expected to show continued growth, though management’s 2026 outlook may lean conservative.

  • Net revenue retention near 120% and more than 4,000 large customers highlight the durability of Datadog’s land-and-expand model.

Current Market Snapshot

Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals. Investors continue to focus on Datadog’s leadership in cloud observability and AI-driven security, supported by strong customer expansion and an increasingly diversified product portfolio. While short-term sentiment has softened, analyst consensus suggests substantial recovery potential as growth catalysts play out.

Recent Developments Influencing Share Performance

Over the past month, Datadog shares have declined approximately 10–15%, mirroring broader weakness in software names and cautious pre-earnings positioning. The pullback followed a strong Q3 2025 earnings report released on November 6, in which revenue climbed 28% year over year to $886 million, exceeding expectations. Adjusted EPS of $0.55 surpassed estimates by more than 20%.

Operationally, Datadog added 210 enterprise customers generating over $100,000 in annual recurring revenue, bringing the total to 4,060. Security-related ARR accelerated at a mid-50% growth rate, while net revenue retention remained steady near 120%, reinforcing the effectiveness of the company’s land-and-expand strategy.

Product momentum continued in December with the announcement of an expanded Strategic Collaboration Agreement with AWS at AWS re:Invent. New capabilities introduced in preview included LLM Observability for Amazon Bedrock Agents, AWS-specific Observability Pipelines Packs, and automated cost optimization tools for Lambda and RDS. While these innovations strengthened Datadog’s positioning in AI infrastructure and cloud monitoring, broader sector rotation muted the immediate market response.

Analyst activity intensified into early 2026. Stifel upgraded the stock to Buy on January 22 with a $205 price target, citing accelerating core growth and potential Q4 upside. DA Davidson reaffirmed a Buy rating with a $225 target on February 2, naming Datadog a top software pick driven by AI momentum. Conversely, several firms trimmed targets due to concerns over 2026 guidance, including KeyBanc ($155 from $170), Rosenblatt ($185 from $200), and Citi ($175). Goldman Sachs initiated coverage with a Sell rating and a $113 target, highlighting competitive pressures from Grafana, Snowflake, and AWS. These mixed signals contributed to heightened volatility, including a 7% single-day drop on February 3.

Macro headwinds, including bearish narratives around software valuations and concerns tied to potential OpenAI workload shifts, further weighed on the stock alongside peers such as Asana and MongoDB. Despite this, Zacks consensus EPS estimates have risen 2.5% over the past 30 days, and Q4 revenue guidance of $912–916 million—representing approximately 24% growth—sets the stage for the upcoming February 10 earnings release. Recent AI-focused launches, including Bits AI SRE, underscore Datadog’s innovation pipeline, though valuation concerns, with the stock trading at a forward P/E above 50x, have capped near-term enthusiasm.

2026 Outlook and Key Factors to Watch

Looking ahead to 2026, investor focus will center on Datadog’s ability to sustain AI-native revenue growth, which accounted for roughly 12% of revenue in recent quarters. Continued expansion in security products—where ARR is growing north of 50%—and deeper integrations with platforms such as AWS Bedrock should support long-term growth as AI workloads scale.

Competitive dynamics remain a key risk, with pressure from observability-focused rivals like Grafana and Chronosphere, as well as potential encroachment from larger platforms such as Snowflake and CrowdStrike. Pricing pressure and customer concentration risks, including high-profile migrations, could introduce volatility. Offsetting these concerns, Datadog’s ecosystem of more than 1,000 integrations and increasing adoption of Bits AI may drive net revenue retention above 120% and support continued growth in large enterprise customers.

Macro conditions, including enterprise cloud spending trends and interest rate sensitivity, will influence management’s guidance posture. Strategic initiatives such as the expanded AWS partnership and hybrid offerings like CloudPrem add diversification. Close attention to post-earnings Q1 guidance and ARR disclosures following the February 10 report will be critical in assessing Datadog’s trajectory within the evolving observability and AI software landscape.

Tickeron AI Perspective

https://tickeron.com/app/ai-robots/signals/all/DDOG/

Disclaimers and Limitations

Related Ticker: DDOG

DDOG's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for DDOG turned positive on August 03, 2026. Looking at past instances where DDOG's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on DDOG as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DDOG advanced for three days, in of 317 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 230 cases where DDOG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DDOG declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DDOG broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DDOG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.707) is normal, around the industry mean (76.065). DDOG's P/E Ratio (738.846) is considerably higher than the industry average of (81.727). Projected Growth (PEG Ratio) (1.799) is also within normal values, averaging (1.688). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (28.571) is also within normal values, averaging (52.041).

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Zoom Communications Inc (NASDAQ:ZM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 11.68B. The market cap for tickers in the group ranges from 291 to 400.64B. QH holds the highest valuation in this group at 400.64B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 3%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 8%. IDAI experienced the highest price growth at 47%, while YAAS experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 7%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 77
Price Growth Rating: 58
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
DDOG
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a company, which engages in the development of monitoring and analytics platform for developers, information technology operations teams and business users

Industry PackagedSoftware

Profile
Details
Industry
N/A
Address
620 8th Avenue
Phone
+1 866 329-4466
Employees
8100
Web
https://www.datadog.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.